As GLP-1 medications have reshaped the treatment of obesity and diabetes for millions worldwide, three peer-reviewed studies now confirm a modestly elevated risk of hair loss among users — a reminder that even transformative medicines carry consequences not fully visible at first light. The relative risk is meaningful, ranging from 37 to 68 percent higher than comparable diabetes drugs, though the absolute numbers remain small. Researchers are not calling for patients to stop treatment, but rather for a more attentive, individualized conversation between patient and clinician — one that holds